开云app官网登录入口网页版-官方正版

#Cabotegravir#

11篇内容 | 1256人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1361443, encodeId=00f4136144305, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=美国批准长效药物Apreude（cabotegravir）用于HIV暴露前预防, objectType=article, longId=292580, objectId=21ce29258046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21ce29258046, replyNumber=0, likeNumber=80, createdTime=2021-12-24, rootId=0, userName=tigerlr98, userId=570c172, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21ce29258046, moduleTitle=美国批准长效药物Apreude（cabotegravir）用于HIV暴露前预防, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=21ce29258046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361442, encodeId=0614136144212, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=NEJM：注射cabotegravir方案用于HIV高危人群暴露前预防, objectType=article, longId=215673, objectId=8b392156e31d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b392156e31d, replyNumber=0, likeNumber=0, createdTime=2021-08-14, rootId=0, userName=tigerlr98, userId=570c172, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b392156e31d, moduleTitle=NEJM：注射cabotegravir方案用于HIV高危人群暴露前预防, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8b392156e31d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361441, encodeId=1af713614412b, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=长效HIV疗法cabotegravir和rilpivirine：病毒抑制持续至96周, objectType=article, longId=208169, objectId=ee55208169eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee55208169eb, replyNumber=0, likeNumber=81, createdTime=2021-03-10, rootId=0, userName=tigerlr98, userId=570c172, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee55208169eb, moduleTitle=长效HIV疗法cabotegravir和rilpivirine：病毒抑制持续至96周, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ee55208169eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361440, encodeId=5297136144092, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号, objectType=article, longId=203543, objectId=df7b20354322, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df7b20354322, replyNumber=0, likeNumber=0, createdTime=2020-11-21, rootId=0, userName=tigerlr98, userId=570c172, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df7b20354322, moduleTitle=ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=df7b20354322)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361439, encodeId=ee8d136143939, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=长效HIV药物Cabotegravir在预防研究中超越了护理标准！, objectType=article, longId=203280, objectId=1550203280a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1550203280a6, replyNumber=0, likeNumber=100, createdTime=2020-11-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1550203280a6, moduleTitle=长效HIV药物Cabotegravir在预防研究中超越了护理标准！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1550203280a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361438, encodeId=58c8136143856, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=Lancet Infect Dis：cabotegravir的PrEP方案可将HIV发病率降低66％, objectType=article, longId=197267, objectId=597819e26795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597819e26795, replyNumber=0, likeNumber=92, createdTime=2020-07-10, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597819e26795, moduleTitle=Lancet Infect Dis：cabotegravir的PrEP方案可将HIV发病率降低66％, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=597819e26795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361437, encodeId=01ac136143e24, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=艾滋病治疗取得新进展：Cabotegravir和rilpivirine的有效性和安全性得以确证, objectType=article, longId=189677, objectId=c5cb1896e713, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5cb1896e713, replyNumber=0, likeNumber=90, createdTime=2020-03-12, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5cb1896e713, moduleTitle=艾滋病治疗取得新进展：Cabotegravir和rilpivirine的有效性和安全性得以确证, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c5cb1896e713)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361436, encodeId=67b41361436a2, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=Biomaterials：研制具有改善的抗逆转录病毒特征的纳米制剂cabotegravir前药, objectType=article, longId=149726, objectId=74d3149e2693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d3149e2693, replyNumber=0, likeNumber=80, createdTime=2018-09-28, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d3149e2693, moduleTitle=Biomaterials：研制具有改善的抗逆转录病毒特征的纳米制剂cabotegravir前药, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74d3149e2693)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361435, encodeId=6ce0136143508, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功, objectType=article, longId=146747, objectId=d9eb146e4766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9eb146e4766, replyNumber=0, likeNumber=86, createdTime=2018-08-17, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9eb146e4766, moduleTitle=每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d9eb146e4766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361434, encodeId=9df41361434e7, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=Lancet：长效抗病毒药物Cabotegravir和利匹韦林联合用于维持HIV-1病毒抑制期的效果, objectType=article, longId=106586, objectId=4e2b1065868d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2b1065868d, replyNumber=0, likeNumber=75, createdTime=2017-07-26, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2b1065868d, moduleTitle=Lancet：长效抗病毒药物Cabotegravir和利匹韦林联合用于维持HIV-1病毒抑制期的效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4e2b1065868d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361433, encodeId=b7811361433d4, content=<a href='/topic/show?id=7161395514' target=_blank style='color:#2F92EE;'>#Cabotegravir#</a>, objectTitle=Lancet Infect Dis：Cabotegravir 加 rilpivirine治疗HIV-1感染新进展（LATTE研究）, objectType=article, longId=53546, objectId=9bf753546a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bf753546a2, replyNumber=0, likeNumber=91, createdTime=2015-07-22, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bf753546a2, moduleTitle=Lancet Infect Dis：Cabotegravir 加 rilpivirine治疗HIV-1感染新进展（LATTE研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9bf753546a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Cabotegravir

2020-05-29

tigerlr98 (审核中...)

前往app查看评论内容

#Cabotegravir#

美国批准长效药物Apreude（cabotegravir）用于HIV暴露前预防

2021-12-24

tigerlr98 (审核中...)

前往app查看评论内容

#Cabotegravir#

NEJM：注射cabotegravir方案用于HIV高危人群暴露前预防

2021-08-14

tigerlr98 (审核中...)

前往app查看评论内容

#Cabotegravir#

长效HIV疗法cabotegravir和rilpivirine：病毒抑制持续至96周

2021-03-10

tigerlr98 (审核中...)

前往app查看评论内容

#Cabotegravir#

ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号

2020-11-21

zhouqu_8 (审核中...)

前往app查看评论内容

#Cabotegravir#

长效HIV药物Cabotegravir在预防研究中超越了护理标准！

2020-11-13

zhouqu_8 (审核中...)

前往app查看评论内容

#Cabotegravir#

Lancet Infect Dis：cabotegravir的PrEP方案可将HIV发病率降低66％

2020-07-10

zhouqu_8 (审核中...)

前往app查看评论内容

#Cabotegravir#

艾滋病治疗取得新进展：Cabotegravir和rilpivirine的有效性和安全性得以确证

2020-03-12

zhouqu_8 (审核中...)

前往app查看评论内容

#Cabotegravir#

Biomaterials：研制具有改善的抗逆转录病毒特征的纳米制剂cabotegravir前药

2018-09-28

zhouqu_8 (审核中...)

前往app查看评论内容

#Cabotegravir#

每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功

2018-08-17

zhouqu_8 (审核中...)

前往app查看评论内容

#Cabotegravir#

Lancet：长效抗病毒药物Cabotegravir和利匹韦林联合用于维持HIV-1病毒抑制期的效果

2017-07-26

zhouqu_8 (审核中...)

前往app查看评论内容

#Cabotegravir#

Lancet Infect Dis：Cabotegravir 加 rilpivirine治疗HIV-1感染新进展（LATTE研究）

2015-07-22

科室
- - 订阅+
  - 更多科室
工具
服务